Phase II study of ipilimumab monotherapy in Japanese patients with advanced melanoma.
作者： N. Yamazaki , Y. Kiyohara , H. Uhara , S. Fukushima , H. Uchi
DOI: 10.1007/S00280-015-2873-X
关键词:
摘要: Purpose Ipilimumab is designed to block cytotoxic T-lymphocyte antigen-4 augment antitumor T cell responses. In studies of predominantly Caucasian patients with advanced melanoma, ipilimumab was associated durable response, long-term survival benefit, and a manageable safety profile. This phase II study assessed the in Japanese unresectable stage III or IV melanoma.
springer.com
elsevier.com
paperity.org
core.ac.uk 参考文章(19)
Karl S Peggs, Sergio A Quezada, Alan J Korman, James P Allison, Principles and use of anti-CTLA4 antibody in human cancer immunotherapy. Current Opinion in Immunology. ,vol. 18, pp. 206- 213 ,(2006) , 10.1016/J.COI.2006.01.011
Karl S. Peggs, Sergio A. Quezada, Cynthia A. Chambers, Alan J. Korman, James P. Allison, Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti–CTLA-4 antibodies Journal of Experimental Medicine. ,vol. 206, pp. 1717- 1725 ,(2009) , 10.1084/JEM.20082492
Frank R. Brennan, Laura Dill Morton, Sebastian Spindeldreher, Andrea Kiessling, Roy Allenspach, Adam Hey, Patrick Müller, Werner Frings, Jennifer Sims, Safety and immunotoxicity assessment of immunomodulatory monoclonal antibodies mAbs. ,vol. 2, pp. 233- 255 ,(2010) , 10.4161/MABS.2.3.11782
Drew M. Pardoll, The blockade of immune checkpoints in cancer immunotherapy Nature Reviews Cancer. ,vol. 12, pp. 252- 264 ,(2012) , 10.1038/NRC3239
Hidehito Horinouchi, Noboru Yamamoto, Yutaka Fujiwara, Ikuo Sekine, Hiroshi Nokihara, Kaoru Kubota, Shintaro Kanda, Shigehiro Yagishita, Hiroshi Wakui, Satoru Kitazono, Hidenori Mizugaki, Takuto Tokudome, Tomohide Tamura, Phase I study of ipilimumab in phased combination with paclitaxel and carboplatin in Japanese patients with non-small-cell lung cancer Investigational New Drugs. ,vol. 33, pp. 881- 889 ,(2015) , 10.1007/S10637-015-0243-5
Katharina C. Kaehler, Sarah Piel, Elisabeth Livingstone, Bastian Schilling, Axel Hauschild, Dirk Schadendorf, Update on Immunologic Therapy With Anti–CTLA-4 Antibodies in Melanoma: Identification of Clinical and Biological Response Patterns, Immune-Related Adverse Events, and Their Management Seminars in Oncology. ,vol. 37, pp. 485- 498 ,(2010) , 10.1053/J.SEMINONCOL.2010.09.003
D. R. Leach, M. F. Krummel, J. P. Allison, Enhancement of antitumor immunity by CTLA-4 blockade. Science. ,vol. 271, pp. 1734- 1736 ,(1996) , 10.1126/SCIENCE.271.5256.1734
F. Stephen Hodi, Steven J. O'Day, David F. McDermott, Robert W. Weber, Jeffrey A. Sosman, John B. Haanen, Rene Gonzalez, Caroline Robert, Dirk Schadendorf, Jessica C. Hassel, Wallace Akerley, Alfons J.M. van den Eertwegh, Jose Lutzky, Paul Lorigan, Julia M. Vaubel, Gerald P. Linette, David Hogg, Christian H. Ottensmeier, Celeste Lebbé, Christian Peschel, Ian Quirt, Joseph I. Clark, Jedd D. Wolchok, Jeffrey S. Weber, Jason Tian, Michael J. Yellin, Geoffrey M. Nichol, Axel Hoos, Walter J. Urba, Improved Survival with Ipilimumab in Patients with Metastatic Melanoma. The New England Journal of Medicine. ,vol. 363, pp. 711- 723 ,(2010) , 10.1056/NEJMOA1003466
Mark J. Selby, John J. Engelhardt, Michael Quigley, Karla A. Henning, Timothy Chen, Mohan Srinivasan, Alan J. Korman, Anti-CTLA-4 Antibodies of IgG2a Isotype Enhance Antitumor Activity through Reduction of Intratumoral Regulatory T Cells Cancer Immunology Research. ,vol. 1, pp. 32- 42 ,(2013) , 10.1158/2326-6066.CIR-13-0013
Jeffrey S. Weber, Katharina C. Kähler, Axel Hauschild, Management of Immune-Related Adverse Events and Kinetics of Response With Ipilimumab Journal of Clinical Oncology. ,vol. 30, pp. 2691- 2697 ,(2012) , 10.1200/JCO.2012.41.6750